Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MND-2119
- Development stage
- Unknown
- Lead developer
- Mochida Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MND-2119 is a novel self-emulsifying formulation of highly purified eicosapentaenoic acid ethyl ester (EPA-E), also known as icosapent ethyl, developed by Mochida Pharmaceutical Company, Ltd. for the treatment of hypertriglyceridemia and hyperlipidemia. Unlike traditional EPA-E formulations that require multiple daily doses and are highly dependent on food intake for absorption, MND-2119 is designed for once-daily administration and features improved bioavailability that is less affected by meals. It was approved in Japan in 2022. The drug functions by reducing hepatic triglyceride synthesis through the inhibition of enzymes such as diacylglycerol O-acyltransferase (DGAT) and fatty acid synthase, while also promoting fatty acid beta-oxidation and enhancing the clearance of triglyceride-rich lipoproteins.
- Brand names
- EPADEL S
- Other names
- icosapent ethyleicosapentaenoic acid ethyl esterEPA-Eself-emulsifying icosapent ethyl
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)DGAT1 (Diacylglycerol O-acyltransferase 1)
Beyond the preview
Go deeper on MND-2119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MND-2119.